| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vitro |
Galantide TFA (0.1-10000 nM) 0.1–10,000 nM) blocks galanin-induced K+ conductance activation with an IC50 value of 4 nM[1]. Galantide TFA (0.1–10,000 nM) has an IC50 value of 16 nM and suppresses voltage-dependent Ba2+ currents in a dose-dependent manner[1]. Regarding voltage-dependent Ba2+ current, the highest inhibition rate of Galantide TFA (0.1–10,000 nM) is almost 40%[1].
|
|---|---|
| ln Vivo |
In rats with ovariectomies, galantide TFA (5 nm; intracerebroventricular injection, once) suppresses the release of luteinizing hormone caused by ovarian steroids [2]. In ovariectomized rats, the luteinizing hormone spike caused by estradiol benzoate is lessened by galantide TFA (1 and 5 nm; intravenously delivered in three split doses at 1300, 1400, and 1500 hours) [2].
|
| Animal Protocol |
Animal/Disease Models: Adult female Crl:CD(SD)BR ovarian steroid-primed ovariectomized (OVX) rats[2]
Doses: 5 nm Route of Administration: Intracerebroventricularly (icv) injection; 5 nm, 60 min before GAL Experimental Results: Blocked GAL-induced LH release. |
| References |
[1]. Mulvaney JM, et al. Galantide distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons. Eur J Pharmacol. 1995 Dec 4;287(1):97-100.
[2]. Sahu A, et al. Role of galanin in stimulation of pituitary luteinizing hormone secretion as revealed by a specific receptor antagonist, galantide. Endocrinology. 1994 Feb;134(2):529-36. |
| Molecular Formula |
C106H152F3N25O28S
|
|---|---|
| Molecular Weight |
2313.55
|
| Related CAS # |
Galantide;138579-66-5
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~43.22 mM)
H2O :< 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4322 mL | 2.1612 mL | 4.3224 mL | |
| 5 mM | 0.0864 mL | 0.4322 mL | 0.8645 mL | |
| 10 mM | 0.0432 mL | 0.2161 mL | 0.4322 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
